Charlotte A. Peterson

Aug 12, 2024 | nature.com | Mary M. McDermott |Christopher Martens |Clara B Peek |Luigi Ferrucci |Philip Greenland |Charlotte A. Peterson

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-49092-5, published online 13 June 2024The abstract for this article was inadvertently truncated after the text ‘…A larger clinical trial to confirm these findings is needed.’; the following text was missing ‘Clinical Trials.gov registration: NCT03743636’. The original article has been updated.

Jun 13, 2024 | nature.com | Mary M. McDermott |Christopher Martens |Clara B Peek |Luigi Ferrucci |Philip Greenland |Charlotte A. Peterson

AbstractPeople with lower extremity peripheral artery disease (PAD) have increased oxidative stress, impaired mitochondrial activity, and poor walking performance. NAD+ reduces oxidative stress and is an essential cofactor for mitochondrial respiration. Oral nicotinamide riboside (NR) increases bioavailability of NAD+ in humans.